Compare KFS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KFS | ETON |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.8M | 411.9M |
| IPO Year | 1996 | 2018 |
| Metric | KFS | ETON |
|---|---|---|
| Price | $13.44 | $15.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 91.4K | ★ 213.4K |
| Earning Date | 03-16-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $128,567,000.00 | $70,316,000.00 |
| Revenue This Year | N/A | $107.23 |
| Revenue Next Year | N/A | $29.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.31 | ★ 102.77 |
| 52 Week Low | $7.06 | $11.09 |
| 52 Week High | $16.80 | $23.00 |
| Indicator | KFS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 40.28 |
| Support Level | $13.18 | $14.62 |
| Resistance Level | $13.56 | $15.41 |
| Average True Range (ATR) | 0.48 | 0.55 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 65.48 | 29.71 |
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.